Women with hereditary breast cancer risk have limited options for management. Close cancer screening or prophylactic mastectomy (PM) is most commonly utilized. Chemoprevention with tamoxifen is another option, but data regarding long-term risk reduction are incomplete and conflicting. Unfortunately, there are insufficient data regarding the expected outcomes with either surveillance or PM. Breast cancers on the chest wall have been documented following PM, developing in residual glandular epithelium. Thus, the extent of risk reduction with PM, if any, has been questioned. The program announcement """"""""Clinical Epidemiology Studies in Hereditary Breast/Ovarian Cancer"""""""" describes the """"""""immediate need to address these issues through retrospective studies based on existing resources"""""""". The Mayo Clinic has served as a referral center for specialized surgeries, including PM, for many years. They have access to two groups of high-risk women who elected PM: unaffected women who have elected contralateral PM and women treated with therapeutic mastectomy for their first breast cancer who elected contralateral, unilateral PM. With the work proposed, the investigators will clarify the magnitude of breast cancer risk reduction with PM using a combination of methods, including standardized morbidity ratios using the Gail and Anderson models to predict the expected number of events, and a relative risk using sisters of women who had PM as a reference group. We will also define short- and long-term complications following PM.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Program Officer
Nayfield, Susan G
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Mutter, Robert W; Frost, Marlene H; Hoskin, Tanya L et al. (2015) Breast cancer after prophylactic mastectomy (bilateral or contralateral prophylactic mastectomy), a clinical entity: presentation, management, and outcomes. Breast Cancer Res Treat 153:183-90
Frost, Marlene H; Hoskin, Tanya L; Hartmann, Lynn C et al. (2011) Contralateral prophylactic mastectomy: long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits. Ann Surg Oncol 18:3110-6
Boughey, Judy C; Hoskin, Tanya L; Degnim, Amy C et al. (2010) Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 17:2702-9
Adem, Camilo; Soderberg, Cheryl L; Hafner, Kari et al. (2004) ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes Cancer 41:1-11
Zion, Sara M; Slezak, Jeffrey M; Sellers, Thomas A et al. (2003) Reoperations after prophylactic mastectomy with or without implant reconstruction. Cancer 98:2152-60
Riggs, B Lawrence; Hartmann, Lynn C (2003) Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. N Engl J Med 348:618-29
Adem, Camilo; Reynolds, Carol; Soderberg, Cheryl L et al. (2003) Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 97:1-11
Sinclair, Colleen S; Adem, Camilo; Naderi, Ali et al. (2002) TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors. Cancer Res 62:3587-91
McDonnell, S K; Schaid, D J; Myers, J L et al. (2001) Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19:3938-43
Hartmann, L C; Sellers, T A; Schaid, D J et al. (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93:1633-7